Dr Max Nobis
Dr Max Nobis studies cancer progression and treatment at the Garvan Institute of Medical Research. Following his MSc in Oncology at the Vrije Universiteit in Amsterdam, he went on to work in Professor Kurt Anderson’s lab at the CRUK Beatson Institute in Glasgow. His PhD project focused on characterising FRET biosensor mice and their use in studying disease progression in mouse models of mammary and pancreatic cancer, as well as their use in monitoring pharmacodynamics in vivo, employing optical window imaging. Max joined Professor Paul Timpson’s lab to apply advanced imaging techniques in the study of pancreatic cancer disease progression and treatment, using FRET biosensor mice in conjunction with genetic mouse models of pancreatic cancer and patient specific biomarkers for the tailoring of personalised treatment regimens.
- 2017Lorne Cancer Conference Poster Prize
- 2018CINSW Early Career Fellowship
- 2018St. Vincent’s Research Week National Meeting Prize
- 2019Hunter Cell Biology International Meeting - Sydney Catalyst Prize
- 2021ANZSCDB Early-Career Researcher Award
- 2023Science advances10.1126/sciadv.adh0831
Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
- 2023Science advances10.1126/sciadv.adf9063
Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse.
- 2023Science advances10.1126/sciadv.abp8314
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma.
- 2022Nature communications10.1038/s41467-022-32255-7
Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis.
- 2021Science advances10.1126/sciadv.abh0363
Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status.